4528:TYO
Ono Pharmaceutical Co Ltd
2Â 333,50Â JPÂ¥
arrow_downward
-1,52%(-36,00) 1K
29-sen, 15:30:00 (GMT+9) · JPY
search
Barcha belgilar
1K
5K
1O
6O
YBB
1Y
5Y
MAKS
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_auto4528 tikeri uchun statistika yaratilmoqda...
Ochish
2Â 388Â JPÂ¥
Yuqori
2Â 388Â JPÂ¥
Past
2Â 331Â JPÂ¥
Bozor kapitali
1,16Â trln
Oʻrtacha hajm
1,45Â mln
Hajmi
1,62Â mln
Dividend
3,43%
Choraklik dividendlar
20Â JPÂ¥
Eks-dividend sanasi
29-sen, 2026
P/E koeffitsiyenti
14,39
52 haftalik eng yuqori
2Â 674Â JPÂ¥
52 haftalik eng past
1Â 678Â JPÂ¥
Aksiya boʻyicha daromad
162Â JPÂ¥
Muomaladagi aksiyalar
514,12Â mln
Xodimlar soni
4Â ming
Ochish
2Â 388Â JPÂ¥
Yuqori
2Â 388Â JPÂ¥
Past
2Â 331Â JPÂ¥
Bozor kapitali
1,16Â trln
Oʻrtacha hajm
1,45Â mln
Hajmi
1,62Â mln
Dividend
3,43%
Choraklik dividendlar
20Â JPÂ¥
Eks-dividend sanasi
29-sen, 2026
P/E koeffitsiyenti
14,39
52 haftalik eng yuqori
2Â 674Â JPÂ¥
52 haftalik eng past
1Â 678Â JPÂ¥
Aksiya boʻyicha daromad
162Â JPÂ¥
Muomaladagi aksiyalar
514,12Â mln
Xodimlar soni
4Â ming
Profil
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
Ono Pharmaceutical Co Ltd haqida
CEOGyo Sagara | Gyo Sagara
Xodimlar soni4,21Â ming
Asos solingan1717
Bosh ofislarOsaka, Osaka, Yaponiya
Sektor-
Veb-saytono-pharma.com